API 0.74% $1.35 australian pharmaceutical industries limited

is there anyone, page-12

  1. 7,719 Posts.
    lightbulb Created with Sketch. 161
    My read is that the ICR will still be at about roughly 3x (EBIT/i), and should be acceptable to lenders. Also the lenders can see SOL sitting on quite a shareholding - if equity was to be required. I'd expect they would be keen to underwrite something and creep up the register. Also a DRP might swing things enough to avoid that. Divs can be cut as well for a year - nobody would like that - lol.

    Re the writedowns - maybe priceline is worth more now with profit improving - however this isn't really reflected in the balance sheet. I suspect that these writedowns have been somewhat factored in - obviously the balance sheet looks a bit more stretched, but market cap is about half the net assets or so after this writedown.

    So I bought the dip for the above reasons - GLTA - div expected in may - could provide a bid too

 
watchlist Created with Sketch. Add API (ASX) to my watchlist

Currently unlisted public company.

arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.